Zenobia Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 5.00 M
as on 22-12-2024
- Paid Up Capital ₹ 4.20 M
as on 22-12-2024
- Company Age 14 Year, 5 Months
- Last Filing with ROC 31 Mar 2021
- Revenue -0.10%
(FY 2018)
- Profit -1901.32%
(FY 2018)
- Ebitda -143.41%
(FY 2018)
- Net Worth 18.90%
(FY 2018)
- Total Assets 48.12%
(FY 2018)
About Zenobia Pharmaceuticals
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2021. It's a company limited by shares with an authorized capital of Rs 5.00 M and a paid-up capital of Rs 4.20 M, as per Ministry of Corporate Affairs (MCA) records.
Ramanan Sankara, Biju Kallazhy, Kavungal Chellan, and Three other members serve as directors at the Company.
- CIN/LLPIN
U24233KL2010PTC026403
- Company No.
026403
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
23 Jul 2010
- Date of AGM
30 Nov 2021
- Date of Balance Sheet
31 Mar 2021
- Listing Status
Unlisted
- ROC Code
Roc Ernakulam
Industry
Company Details
- Location
Kozhikode, Kerala, India
- Telephone
- Email Address
- Website
- Social Media
Who are the key members and board of directors at Zenobia Pharmaceuticals?
Executive Team (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Ramanan Sankara  | Managing Director | 23-Jul-2010 | Current |
Board Members(5)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Biju Kallazhy | Director | 23-Jul-2010 | Current |
| Kavungal Chellan | Director | 24-Jan-2019 | Current |
| Anandan Raman | Director | 24-Jan-2019 | Current |
| Dharmaraj Kumar | Director | 24-Jan-2019 | Current |
| Sreekumar Dharmaraj | Director | 23-Jul-2010 | Current |
Financial Performance of Zenobia Pharmaceuticals.
Zenobia Pharmaceuticals Private Limited, for the financial year ended 2018, experienced Minor drop in revenue, with a 0.1% decrease. The company also saw a substantial fall in profitability, with a 1901.32% decrease in profit. The company's net worth Soared by an impressive increase of 18.9%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Zenobia Pharmaceuticals?
In 2018, Zenobia Pharmaceuticals had a promoter holding of 39.52% and a public holding of 60.48%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Zenobia Pharmaceuticals?
Unlock and access historical data on people associated with Zenobia Pharmaceuticals, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Zenobia Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Zenobia Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
